25 years of pioneering in dementia research

The Alzheimer Centre Limburg (ACL) is celebrating its 25th anniversary this year. The Maastricht-based centre now has three research lines, in which scientists collaborate on various aspects of dementia. What has all this research achieved for people with dementia and their loved ones? The three professors at the helm explain, starting with ‘Risk and prevention’, followed by ‘Diagnostics and disease mechanisms’, and finally ‘Psychosocial innovations’.

Prof. dr. Sebastian Köhler is leading the 'Risk and prevention' research line

“Twenty-five years ago, there was absolutely no focus on preventing dementia. At that time, it became possible to diagnose Alzheimer’s in living patients using cerebrospinal fluid. That gave great hope for the development of a drug that would cure the disease. When that failed to materialise, support grew for a greater focus on prevention. Over the past ten to fifteen years, the importance of this has increased enormously. In 2019, the World Health Organisation (WHO) published its first guideline on this subject, and my group is currently contributing to its revision. Such a guideline brings together all the knowledge on treatments that reduce the risk of dementia and translates it into global practice. Being able to contribute to such a guideline is the crowning achievement of my work. It is also a wonderful recognition of the work here in Maastricht: we are seen as pioneers. And that, in turn, is based on the research of the past 25 years, which has always had one goal: to help people age more healthily.

For that goal, we have, for example, developed a score for the risk factors associated with the development of dementia: the LIBRA score (LIfestyle for BRAin health). This score is used worldwide to inform people about what they can do to reduce their personal risk. With funding from the Province of Limburg, we also developed an awareness campaign in 2018: ‘We are the medicine’. We developed the ‘MijnBreincoach’ app, which allows people to check their LIBRA score themselves and receive advice on how to work on their lifestyle. This campaign has been adopted in nine GGD regions and recognised by the WHO as a model for other countries. The app has now been translated and is available in Luxembourg, with Germany to follow shortly.  

Change begins with awareness: the realisation that you can take action yourself to reduce your risk of dementia. That is why we are working nationwide to find ways of getting this evidence across to the public. In particular, to people who are somewhat removed from this kind of health message, such as those on lower incomes or from migrant backgrounds. You also realise that it is not the most pressing issue for everyone. There are often other concerns besides lifestyle, let alone lifestyle in relation to dementia. There may also be limits to what you can expect from an individual. Ultimately, it is also a societal problem: if you live in an environment where everything encourages unhealthy behaviour, it is very difficult to work on your health.

That is why, in the coming years, we are focusing on a more neighbourhood-based approach: can we work together on brain health, with GPs, schools, local authorities and all the stakeholders in a neighbourhood? And I hope that the government will also take ownership of the problem, so that national campaigns on prevention are launched. In addition to a healthy lifestyle, people can continue to stimulate their brains. Staying curious, learning new things such as a musical instrument or a language, but also having a conversation is a top-level activity, during which the brain creates new connections. The more, the better. I compare it to roads. If you have two roads between A and B and one is blocked, you have to take a bit of a detour, but you still get there. If you only have one road and it’s blocked, you’ve got a problem. So continuing to make those connections throughout your life is very important for better protection against dementia later on.”

Sebastian Köhler

Prof. dr. Pieter Jelle Visser is leading the ‘Diagnostics and disease mechanisms' research line

“At the start of my career, I had the choice between researching diabetes or Alzheimer’s. There was still so much to discover in the latter field. There was no cure yet, and it all revolved around the brain: absolutely fascinating. At that time, a diagnosis of dementia could only be made after death; in the brains of these people, researchers found ‘clumps’ of the amyloid protein in plaques. About seven years later, a method was developed to measure this in the cerebrospinal fluid of living people; a tremendous step forward in this research. You can track how protein clumping develops in the brain over time. A second protein that plays a role in dementia, tau, could also be measured in this way; we call these biomarkers. We can now also measure these proteins in blood, or visualise them using a PET scan. Our group has shown that there is a long interval between the formation of plaques containing protein deposits and the onset of dementia. Many people die with plaques already present before they become ill.

Recent studies have shown that antibodies can clear away plaques, slowing cognitive decline by up to 40%. And in 2024, we published a paper in Nature on the five different types of Alzheimer’s disease that we had identified. It turns out that one subgroup has higher levels of inflammation in the brain. Naturally, you hope that this knowledge will contribute to the development of a drug to treat dementia. The drug lecanemab, which the Dutch Healthcare Institute recently advised the government not to include in the basic health insurance package, is one such antibody that clears away the plaques. The fact that it works is magical, but we’re not there yet: the effect of the antibody on the progression of the disease is modest. At the same time, we believe it could well have an effect on a specific subtype of Alzheimer’s. That is the added value of these subtypes.

To investigate this, we need a great deal of patient data, and the challenge is that these are often held by pharmaceutical companies. We therefore also devote part of our time to making these kinds of databases accessible for research. By studying large groups, we were able to identify the subtypes at the protein level. But we were also able to discover, for example, the genes linked to the subtypes. People with a specific mutation in that gene develop Alzheimer’s, sometimes even at a young age. In the coming years, we will investigate the subtypes of Alzheimer’s further. It makes the research more complex, but hopefully also more effective for drug development. This principle may also play a role in other brain diseases. And I hope to advance the studies into antibodies as a treatment. So far, it has emerged that patients who received antibodies felt better as a group and required less care: that is remarkable. The effects are not yet significant enough, but with further research, the effects may become stronger.”

Pieter Jelle Visser

Prof. dr. Marjolein de Vugt is leading the Alzheimer Centre Limburg and the ‘Psychosocial innovations' research line

“At the outset, we were primarily interested in understanding what life is like for people with dementia and their loved ones. What happens during their interactions? The disease has a significant impact on the environment, and the role imposed on the loved one is a complex one with far-reaching consequences. Research has shown that how the loved one copes with and responds to the person with dementia also appears to influence the well-being of the person with dementia. If you do not fully understand what is happening to the other person, you may sometimes react as you always have, but this no longer goes down well with the person with dementia, leading to arguments, tension or conflict. People also differ in how much support they seek from others, and this partly determines whether you still experience a good quality of life during such a disease process. We have translated this into support programmes through which we can help people. 

In 2011, we launched ‘Partner in Balance’. If, for example, your network seems small, or you think it’s better not to share with others, we explain that openness within your circle ensures you’re not on your own, even when things get tougher. The disease process continues, and we try to teach loved ones the skills to climb the mountains that arise in the right way, so they feel more in control of daily life. Every form of dementia progresses differently, and every loved one is different. Meanwhile, a major study is underway in England to explore how Partner in Balance can be introduced there, so they don’t have to reinvent the wheel. In recent years, we have continued to adapt Partner in Balance to specific target groups. We have also learnt that we need to involve the target groups in this process, which we do through a client panel.

We are currently exploring how we can use technology, such as artificial intelligence, to make support programmes more effective, without necessarily involving a professional. As the number of people with dementia rises, the pressure on the care sector is increasing, so I believe this is the way forward. Not to replace professionals, but to be able to offer something to those on the waiting list as well. We are also looking at how technology can support people with dementia, for example to maintain their day-night rhythm and improve sleep quality. This is so that professional care, and admission to a care home, can be postponed for as long as possible. That is the wish of people with dementia and their loved ones. Another growing area of focus is keeping care accessible to everyone, including people with less education or language proficiency. How do we build a community around older Turkish and Moroccan people? Journalists often ask about ‘the breakthrough of the past 25 years’. I’m not looking for that; I’m looking for small steps that make a difference to individuals, based on the stories of the people themselves. That’s inspiring work to do.”

Marjolein de Vugt

ACL in brief

The Alzheimer Centre Limburg (ACL) was established 25 years ago as the first centre of its kind in the Netherlands. Fifteen years prior to that, the first Memory Clinic was also set up at Maastricht UMC+. Here, scientific research and healthcare innovation go hand in hand. The three professors featured in this story lead research teams that join forces with scientists worldwide through various consortia and partnerships. In addition, the ACL sets up community projects to inform a wide audience, but also to reduce the stigma surrounding dementia. Incidentally, Alzheimer’s is the most common form of dementia, hence the name, but the Alzheimer Centre Limburg also focuses on other forms of dementia.

Read more about the Alzheimer Centrum Limburg.

 

This article was previously published on the Maastricht UMC+ website.
Photo's: Johan Latupeirissa en Joey Roberts

Also read

  • The delayed diagnosis of endometriosis

    In Honours+, students gain their first experience in approaching (global) challenges in an interdisciplinary setting, under the professional guidance of staff members from Maastricht University.
    UM news
    honours endometriosis
  • Creating an identity card with DNA

    By looking at just a few letters in your genome, researchers can roughly tell your age, and if you are a smoker or stopped smoking. Athina Vidaki uses these genetic techniques to help solve sexual assault cases.
    Athina Vidaki